You just read:

Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease

News provided by

Protalix BioTherapeutics, Inc.

Oct 17, 2019, 07:40 ET